Establishment Labs (NASDAQ:ESTA) Releases Earnings Results, Misses Estimates By $0.34 EPS

Establishment Labs (NASDAQ:ESTA) released its earnings results on Wednesday. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.34), Zacks reports. The company had revenue of $44.51 million for the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%.

Establishment Labs Stock Performance

NASDAQ ESTA traded up $0.30 during trading on Friday, reaching $42.83. The company’s stock had a trading volume of 189,672 shares, compared to its average volume of 672,284. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -16.52 and a beta of 1.12. Establishment Labs has a 12 month low of $28.16 and a 12 month high of $60.12. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The firm has a 50 day moving average price of $37.45 and a 200 day moving average price of $41.34.

Wall Street Analysts Forecast Growth

Separately, Stephens reissued an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.40.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.